Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | F2R | P25116 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 3/20 | 0.45 |
| ▸ | RAB9A | P51151 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3310873 | 0.89 | KDM4E (0.56) | SMN1; SMN2KDM4EHSD17B10POLBCYP1A2 | |
| SCHEMBL17199511 | 0.84 | KDM4E (0.51) | SMN1; SMN2KDM4EHSD17B10POLBCYP1A2 | |
| SCHEMBL23771028 | 0.83 | HTT (0.44) | SMN1; SMN2KDM4ETSHRPOLBMEN1 | |
| SCHEMBL28467090 | 0.82 | KDM4E (0.60) | SMN1; SMN2KDM4ENPSR1HSD17B10POLB | |
| SCHEMBL17174227 | 0.80 | KDM4E (0.48) | SMN1; SMN2KDM4EHSD17B10POLBCYP1A2 | |
| SCHEMBL17174934 | 0.80 | KDM4E (0.48) | SMN1; SMN2KDM4EHSD17B10POLBCYP1A2 | |
| SCHEMBL29428097 | 0.80 | CYP2C9 (0.60) | SMN1; SMN2KDM4EHSD17B10POLBCYP1A2 | |
| SCHEMBL24202501 | 0.79 | KDM4E (0.47) | SMN1; SMN2KDM4ENPSR1HSD17B10POLB | |
| SCHEMBL3668355 | 0.79 | GAA (0.58) | SMN1; SMN2KDM4ETSHRPOLBCYP1A2 | |
| SCHEMBL1454511 | 0.79 | POLB (0.62) | SMN1; SMN2TSHRPOLBMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228493-A1 | LRRK2 INHIBITORS AND USES THEREOF | NEURON23, INC. | 2024-07-11 | — | — | US | disclosed |
| US-20240228493-A1 | LRRK2 INHIBITORS AND USES THEREOF | NEURON23, INC. | 2024-07-11 | — | — | US | disclosed |
| US-11858939-B2 | Hetero-halo inhibitors of histone deacetylase | ALKERMES, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| WO-2023274251-A1 | POLYCYCLIC COMPOUND FOR INHIBITING RNA HELICASE DHX33, AND APPLICATION OF COMPOUND | 深圳开悦生命科技有限公司 | 2023-01-05 | — | — | WO | disclosed |
| EP-3063143-B1 | AMINOHETEROARYL BENZAMIDES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2018-05-16 | — | — | EP | disclosed |
| US-9957259-B2 | Selective HDAC1 and HDAC2 inhibitors | REGENACY PHARMACEUTICALS, LLC (US) | 2018-05-01 | — | — | US | disclosed |
| US-20180030040-A1 | SELECTIVE HDAC1 AND HDAC2 INHIBITORS | ACETYLON PHARMACEUTICALS, INC. | 2018-02-01 | — | — | US | disclosed |
| US-20180028532-A1 | AMINOHETEROARYL BENZAMIDES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2018-02-01 | — | — | US | disclosed |
| US-9763937-B2 | Aminoheteroaryl benzamides as kinase inhibitors | NOVARTIS AG (CH) | 2017-09-19 | — | — | US | disclosed |
| US-9765066-B2 | Selective HDAC1 and HDAC2 inhibitors | REGENACY PHARMACEUTICALS, LLC (US) | 2017-09-19 | — | — | US | disclosed |
| US-20140128391-A1 | SELECTIVE HDAC1 AND HDAC2 INHIBITORS | REGENACY PHARMACEUTICALS, LLC | 2014-05-08 | — | — | US | disclosed |
| US-20070249600-A1 | CHEMICAL COMPOUNDS | CHEUNG MUI | 2007-10-25 | — | — | US | disclosed |
| US-20070249600-A1 | CHEMICAL COMPOUNDS | CHEUNG MUI | 2007-10-25 | — | — | US | disclosed |
| US-20070249600-A1 | CHEMICAL COMPOUNDS | CHEUNG MUI | 2007-10-25 | — | — | US | disclosed |
| US-7238813-B2 | Chemical compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2007-07-03 | — | — | US | disclosed |
| US-7238813-B2 | Chemical compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2007-07-03 | — | — | US | disclosed |
| US-7238813-B2 | Chemical compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2007-07-03 | — | — | US | disclosed |
| US-20040082583-A1 | Chemical compounds | SMITHKLINE BEECHAM CORPORATION | 2004-04-29 | — | — | US | disclosed |
| EP-1341771-A2 | BENZIMIDAZOLE DERIVATIVES USEFUL AS TIE-2 AND/OR VEGFR-2 INHIBITORS | GLAXO GROUP LIMITED (GB) | 2003-09-10 | — | — | EP | disclosed |
| WO-2002044156-A2 | BENZIMIDAZOLE DERIVATIVES USEFUL AS TIE-2 AND/OR VEGFR-2 INHIBITORS | GLAXO GROUP LIMITED (GB) | 2002-06-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11858939-B2 | Hetero-halo inhibitors of histone deacetylase | HDAC2, HDAC1, HDAC6 | SMN1; SMN2 1652/4885KDM4E 1323/4885NPSR1 1439/4885 |
| US-20070249600-A1 | CHEMICAL COMPOUNDS | TIE1, KDR, FLT4 | SMN1; SMN2 4300/4885KDM4E 244/4885NPSR1 4582/4885 |
| US-20040082583-A1 | Chemical compounds | TIE1, KDR, FLT4 | SMN1; SMN2 4300/4885KDM4E 244/4885NPSR1 4582/4885 |
| US-20180030040-A1 | SELECTIVE HDAC1 AND HDAC2 INHIBITORS | HDAC1, HDAC2, HDAC11 | SMN1; SMN2 488/4885KDM4E 1010/4885NPSR1 4704/4885 |
| US-20180028532-A1 | AMINOHETEROARYL BENZAMIDES AS KINASE INHIBITORS | ABL1, MAP3K12, MAP3K2 | SMN1; SMN2 4410/4885KDM4E 657/4885NPSR1 3361/4885 |
| US-20240228493-A1 | LRRK2 INHIBITORS AND USES THEREOF | LRRK2, PINK1, PARK7 | SMN1; SMN2 778/4885KDM4E 2452/4885NPSR1 4495/4885 |
| US-20140128391-A1 | SELECTIVE HDAC1 AND HDAC2 INHIBITORS | HDAC1, HDAC2, HDAC11 | SMN1; SMN2 488/4885KDM4E 1010/4885NPSR1 4704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.